港股异动 | 碧生源涨5.26% 中期扭亏为盈至1.67亿元
格隆汇8月28日丨碧生源(00926.HK)涨5.26%,报0.4港元,成交100.47万港元,总市值6.5亿港元。碧生源上周公布中期业绩,公司收益3.38亿元人民币,同比增长101.7%;毛利2.47亿元,同比增长103%;公司股东应占溢利1.67亿元,上年同期亏损2619.5万元;毛利率73%,同比上升0.5个百分点。从各分部业绩的数据分析,碧生源新老产品两线开花。两茶(碧生源常润茶和常菁茶)的销售收入同比上升60%;奥利司他减肥药业务同比则几乎翻了4倍,从2018年同期的2290万元上升为1.089亿元,已经成为碧生源的重要业务组分。在本次中期业绩发布的同时,碧生源宣告发放每股11分港币的股息,优先兑现了之前对股民的承诺。根据中报数据,目前,碧生源账面现金充裕(含银行理财和票据)近4.5亿,分配股息后,还有充足的现金进行运营和扩张。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.